US6558952B1
(en)
*
|
1992-12-14 |
2003-05-06 |
Waratah Pharmaceuticals, Inc. |
Treatment for diabetes
|
US20040037818A1
(en)
*
|
1998-07-30 |
2004-02-26 |
Brand Stephen J. |
Treatment for diabetes
|
ATE445006T1
(de)
|
1998-08-10 |
2009-10-15 |
Us Gov Health & Human Serv |
Differenzierung von nicht-insulin in insulin- produzierende zellen durch glp-1 und exendin-4 und dessen verwendung
|
ATE482717T1
(de)
|
1999-02-10 |
2010-10-15 |
Curis Inc |
Peptid yy (pyy) zur behandlung von glukose stoffwechselkrankheiten
|
US7745216B2
(en)
*
|
1999-02-10 |
2010-06-29 |
Curis, Inc. |
Methods and reagents for treating glucose metabolic disorders
|
DE19921537A1
(de)
*
|
1999-05-11 |
2000-11-23 |
Dieter Hoersch |
Verfahren zur Induzierung von Zellwachstum durch Verwendung geeigneter Mittel
|
AU1269501A
(en)
*
|
1999-11-12 |
2001-05-30 |
Novo Nordisk A/S |
Use of glp-1 agonists for the inhibition of beta cell degeneration
|
US6569832B1
(en)
|
1999-11-12 |
2003-05-27 |
Novo Nordisk A/S |
Inhibition of beta cell degeneration
|
US7022674B2
(en)
|
1999-12-16 |
2006-04-04 |
Eli Lilly And Company |
Polypeptide compositions with improved stability
|
KR20080067009A
(ko)
|
2000-03-31 |
2008-07-17 |
프로시디온 리미티드 |
디펩티딜 펩티다제 ⅳ 효소 활성 억제제를 포함하는약제학적 조성물
|
CZ304002B6
(cs)
*
|
2000-06-16 |
2013-08-14 |
Eli Lilly And Company |
Analogy peptidu-1 podobného glukagonu
|
EP1891948A1
(de)
|
2000-10-27 |
2008-02-27 |
Probiodrug AG |
Behandlung von neurologischen und neuropsychologischen Störungen
|
BR0116206A
(pt)
*
|
2000-12-14 |
2003-12-23 |
Amylin Pharmaceuticals Inc |
Peptìdeo yy e agonistas de peptìdeo yy para tratamento de distúrbios metabólicos
|
JP4227894B2
(ja)
*
|
2001-08-23 |
2009-02-18 |
イーライ リリー アンド カンパニー |
グルカゴン様ペプチド1アナログ
|
WO2003020201A2
(en)
*
|
2001-08-28 |
2003-03-13 |
Eli Lilly And Company |
Pre-mixes of glp-1 and basal insulin
|
JP5424521B2
(ja)
|
2001-12-21 |
2014-02-26 |
ヒューマン ジノーム サイエンシーズ, インコーポレイテッド |
アルブミン融合タンパク質
|
AU2003200839B2
(en)
|
2002-01-08 |
2008-12-11 |
Eli Lilly And Company |
Extended glucagon-like peptide-1 analogs
|
CN1332711C
(zh)
|
2002-02-20 |
2007-08-22 |
埃米球科技有限公司 |
施用glp-1分子的方法
|
JP2005527224A
(ja)
*
|
2002-05-24 |
2005-09-15 |
ワラタ ファーマシューティカルズ, インコーポレイテッド |
糖尿病の処置
|
EP1511509B1
(de)
|
2002-06-07 |
2007-10-10 |
Waratah Pharmaceuticals, Inc. |
Zusammensetzungen und verfahren zur behandlung von diabetes
|
WO2003105763A2
(en)
*
|
2002-06-14 |
2003-12-24 |
Amylin Pharmaceuticals, Inc. |
Prevention and/or treatment of inflammatory bowel disease using pyy or agonists thereof
|
ES2320754T3
(es)
*
|
2002-10-22 |
2009-05-28 |
Waratah Pharmaceuticals, Inc. |
Tratamiento de la diabetes.
|
AU2003256988A1
(en)
*
|
2002-12-11 |
2004-06-30 |
Amylin Pharmaceuticals, Inc. |
Methods and compositions for treating polycystic ovary syndrome
|
CN1816622B
(zh)
|
2003-03-28 |
2011-06-22 |
株式会社三和化学研究所 |
高产重组蛋白的植物贮藏器官的生产方法以及新型重组蛋白
|
MXPA05011861A
(es)
|
2003-05-05 |
2006-02-17 |
Probiodrug Ag |
Uso de efectores de ciclasas de glutamato y glutaminil.
|
US7371871B2
(en)
|
2003-05-05 |
2008-05-13 |
Probiodrug Ag |
Inhibitors of glutaminyl cyclase
|
KR20100106630A
(ko)
|
2003-05-05 |
2010-10-01 |
프로비오드룩 아게 |
글루타미닐 및 글루타메이트 사이클라제의 이펙터의 용도
|
ATE549028T1
(de)
|
2003-05-15 |
2012-03-15 |
Tufts College |
Stabile analoga von glp-1
|
MXPA05013565A
(es)
|
2003-06-12 |
2006-03-09 |
Lilly Co Eli |
Proteinas de fusion analogas al glp-1.
|
US20060228331A1
(en)
*
|
2003-10-10 |
2006-10-12 |
Novo Nordisk A/S |
IL-21 Derivatives and variants
|
JP5707014B2
(ja)
|
2003-10-15 |
2015-04-22 |
プロビオドルグ エージー |
グルタミニル、及びグルタミン酸シクラーゼのエフェクターの使用
|
EP2338490A3
(de)
|
2003-11-03 |
2012-06-06 |
Probiodrug AG |
Zusammenstellungen zur Behandlung von neuronalen Erkrankungen
|
US20060287221A1
(en)
*
|
2003-11-13 |
2006-12-21 |
Novo Nordisk A/S |
Soluble pharmaceutical compositions for parenteral administration comprising a GLP-1 peptide and an insulin peptide of short time action for treatment of diabetes and bulimia
|
JP4865565B2
(ja)
*
|
2003-12-09 |
2012-02-01 |
ノヴォ ノルディスク アー/エス |
Glp−1アゴニストを用いた食物選択の制御
|
US20060286129A1
(en)
|
2003-12-19 |
2006-12-21 |
Emisphere Technologies, Inc. |
Oral GLP-1 formulations
|
BRPI0507189A
(pt)
*
|
2004-01-30 |
2007-06-26 |
Waratah Pharmaceuticals Inc |
uso combinado de um agonista de glp-1 e compostos de gastrina
|
EP1713780B1
(de)
|
2004-02-05 |
2012-01-18 |
Probiodrug AG |
Neue inhibitoren von glutaminylcyclase
|
WO2005077094A2
(en)
*
|
2004-02-11 |
2005-08-25 |
Amylin Pharmaceuticals, Inc. |
Pancreatic polypeptide family motifs and polypeptides comprising the same
|
EP1874339A1
(de)
*
|
2005-04-21 |
2008-01-09 |
Gastrotech Pharma A/S |
Pharmazeutische zubereitungen eines glp-1-moleküls und eines antiemetikums
|
ME02786B
(me)
|
2005-05-13 |
2011-10-31 |
Lilly Co Eli |
Glp-1 pegilovana jedinjenja
|
US7737155B2
(en)
|
2005-05-17 |
2010-06-15 |
Schering Corporation |
Nitrogen-containing heterocyclic compounds and methods of use thereof
|
AU2006265814B2
(en)
|
2005-06-30 |
2012-05-10 |
Ipsen Pharma S.A.S. |
GLP-1 pharmaceutical compositions
|
NZ566799A
(en)
|
2005-09-14 |
2011-04-29 |
Takeda Pharmaceutical |
Dipeptidyl peptidase inhibitors for treating diabetes
|
CN101360723A
(zh)
|
2005-09-16 |
2009-02-04 |
武田药品工业株式会社 |
制备嘧啶二酮衍生物的方法
|
JP4860700B2
(ja)
|
2005-09-20 |
2012-01-25 |
シェーリング コーポレイション |
ヒスタミンH3アンタゴニストとして有用な、1−[[1−[(2−アミノ−6−メチル−4−ピリジニル)メチル]−4−フルオロ−4−ピペリジニル]カルボニル]−4−[2−(2−ピリジニル)−3H−イミダゾ[4,5−b]ピリジン−3−イル]ピペリジン
|
EP1942115A4
(de)
*
|
2005-10-26 |
2009-03-18 |
Chugai Pharmaceutical Co Ltd |
Agglutinierbares glp-1-analog und pharmazeutische zusammensetzung mit verzögerter freisetzung
|
NZ571761A
(en)
|
2006-04-12 |
2010-07-30 |
Probiodrug Ag |
5-phenylimidazoles
|
TW200838536A
(en)
|
2006-11-29 |
2008-10-01 |
Takeda Pharmaceutical |
Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
|
WO2008065141A1
(en)
|
2006-11-30 |
2008-06-05 |
Probiodrug Ag |
Novel inhibitors of glutaminyl cyclase
|
JP5667440B2
(ja)
|
2007-04-18 |
2015-02-12 |
プロビオドルグ エージー |
グルタミニルシクラーゼ阻害剤としてのチオ尿素誘導体
|
CA2703203C
(en)
|
2007-10-22 |
2015-12-15 |
Schering Corporation |
Bicyclic heterocycle derivatives and methods of use thereof
|
EP2297117B1
(de)
|
2008-05-19 |
2012-10-31 |
Merck Sharp & Dohme Corp. |
Bicyclische heterocyclusderivate und deren verwendung als gpr119-modulatoren
|
MX2011000664A
(es)
|
2008-07-16 |
2011-02-24 |
Schering Corp |
Derivados biciclicos heterociclicos y uso de los mismos como moduladores de gpr119.
|
WO2010027567A2
(en)
|
2008-07-23 |
2010-03-11 |
Schering Corporation |
Tricyclic spirocycle derivatives and methods of use thereof
|
JP2012504630A
(ja)
|
2008-10-03 |
2012-02-23 |
シェーリング コーポレイション |
グルカゴン受容体アンタゴニストとしてのスピロイミダゾロン誘導体
|
EP2350048A2
(de)
|
2008-10-16 |
2011-08-03 |
Schering Corporation |
Azinderivate und verfahren zu deren anwendung
|
WO2010059602A2
(en)
|
2008-11-19 |
2010-05-27 |
Schering Corporation |
Inhibitors of diacylglycerol acyltransferase
|
US20110243940A1
(en)
|
2008-12-16 |
2011-10-06 |
Schering Corporation |
Bicyclic pyranone derivatives and methods of use thereof
|
US20110245209A1
(en)
|
2008-12-16 |
2011-10-06 |
Schering Corporation |
Pyridopyrimidine derivatives and methods of use thereof
|
EP2379565A1
(de)
|
2008-12-19 |
2011-10-26 |
Schering Corporation |
Piperidin- und piperazinderivate und verfahren zu deren verwendung
|
WO2010071819A1
(en)
|
2008-12-19 |
2010-06-24 |
Schering Corporation |
Bicyclic heterocyclic derivatives and methods of use thereof
|
WO2010075273A1
(en)
|
2008-12-23 |
2010-07-01 |
Schering Corporation |
Bicyclic heterocycle derivatives and methods of use thereof
|
CA2747807A1
(en)
|
2008-12-23 |
2010-07-01 |
Bernard R. Neustadt |
Pyrimidine derivatives and methods of use thereof
|
US8410122B2
(en)
|
2008-12-23 |
2013-04-02 |
Merck Sharp & Dohme Corp. |
Bicyclic heterocycle derivatives and methods of use thereof
|
EP2216042A1
(de)
|
2009-02-09 |
2010-08-11 |
Ipsen Pharma S.A.S. |
GLP1-analoge pharmazeutische Zusammensetzungen
|
WO2010093802A2
(en)
*
|
2009-02-11 |
2010-08-19 |
The General Hospital Corporation |
Therapeutic method for increasing pancreatic beta cell mass
|
ES2493618T3
(es)
|
2009-02-12 |
2014-09-12 |
Proyecto De Biomedicina Cima, S.L. |
Uso de la cardiotrofina-1 para el tratamiento de enfermedades metabólicas
|
WO2010107765A1
(en)
|
2009-03-18 |
2010-09-23 |
Schering Corporation |
Bicyclic compounds as inhibitors of diacylglycerol acyltransferase
|
AR076024A1
(es)
|
2009-04-03 |
2011-05-11 |
Schering Corp |
Derivados de heterociclos biciclicos puenteados y metodos de uso de los mismos
|
US8580807B2
(en)
|
2009-04-03 |
2013-11-12 |
Merck Sharp & Dohme Corp. |
Bicyclic piperidine and piperazine derivatives as GPCR modulators for the treatment of obesity, diabetes and other metabolic disorders
|
US8614185B2
(en)
|
2009-05-04 |
2013-12-24 |
Centocor Ortho Biotech Inc. |
Fusion proteins of alpha-MSH derivatives and Fc
|
WO2010129248A1
(en)
|
2009-05-06 |
2010-11-11 |
Centocor Ortho Biotech Inc. |
Melanocortin receptor binding conjugates
|
EP2440553B1
(de)
|
2009-06-12 |
2017-08-23 |
Merck Sharp & Dohme Corp. |
Thiophene als glucagonrezeptorantagonisten, zusammensetzungen und verfahren zu ihrer verwendung
|
WO2011031628A1
(en)
|
2009-09-14 |
2011-03-17 |
Schering Corporation |
Inhibitors of diacylglycerol acyltransferase
|
US8759357B2
(en)
|
2009-10-08 |
2014-06-24 |
Merck Sharp & Dohme Corp. |
Inhibitors of fatty acid binding protein (FABP)
|
AU2010313469A1
(en)
|
2009-10-29 |
2012-06-07 |
Merck Sharp & Dohme Corp. |
Bridged Bicyclic Piperidine Derivatives and methods of use thereof
|
US8912206B2
(en)
|
2009-11-23 |
2014-12-16 |
Merck Sharp & Dohme Corp. |
Pyrimidine ether derivatives and methods of use thereof
|
US20120232073A1
(en)
|
2009-11-23 |
2012-09-13 |
Santhosh Francis Neelamkavil |
Fused bicyclic pyrimidine derivatives and methods of use thereof
|
WO2011066137A1
(en)
|
2009-11-24 |
2011-06-03 |
Schering Corporation |
Substituted biaryl derivatives and methods of use thereof
|
TWI484974B
(zh)
*
|
2009-12-16 |
2015-05-21 |
Novo Nordisk As |
雙重醯化glp-1衍生物
|
ES2481823T3
(es)
|
2010-03-10 |
2014-07-31 |
Probiodrug Ag |
Inhibidores heterocíclicos de glutaminil ciclasa (QC, EC 2.3.2.5)
|
JP5827218B2
(ja)
|
2010-04-30 |
2015-12-02 |
株式会社三和化学研究所 |
生理活性物質等の生体内安定性向上のためのペプチド及び生体内安定性が向上した生理活性物質
|
RU2013103763A
(ru)
|
2010-07-02 |
2014-08-10 |
Ангиохем Инк. |
Короткие и содержащие d-аминокислоты полипептиды для терапевтических конъюгатов и их применения
|
PL2651398T3
(pl)
|
2010-12-16 |
2018-05-30 |
Novo Nordisk A/S |
Stałe kompozycje zawierające agonistę GLP-1 i sól kwasu N-(8-(2-hydroksybenzoilo)amino)kaprylowego
|
EP2686313B1
(de)
|
2011-03-16 |
2016-02-03 |
Probiodrug AG |
Benzimidazolderivate als glutaminylcyclase-hemmer
|
EP3225631B1
(de)
*
|
2011-04-12 |
2019-01-09 |
Novo Nordisk A/S |
Zweifach acylierte glp-1-derivate
|
ES2952874T3
(es)
|
2012-03-22 |
2023-11-06 |
Novo Nordisk As |
Composiciones de péptidos GLP-1 y preparación de estas
|
HUE042757T2
(hu)
|
2012-03-22 |
2019-07-29 |
Novo Nordisk As |
Szállító szert tartalmazó készítmények és elõállításuk
|
CN104411322B
(zh)
|
2012-05-08 |
2017-05-24 |
诺和诺德股份有限公司 |
双酰化glp‑1衍生物
|
JP6250034B2
(ja)
|
2012-05-08 |
2017-12-20 |
ノヴォ ノルディスク アー/エス |
二重アシル化されたglp−1誘導体
|
JP6517690B2
(ja)
|
2012-06-20 |
2019-05-22 |
ノヴォ ノルディスク アー/エス |
ペプチド及び送達剤を含む錠剤製剤
|
PE20151770A1
(es)
|
2013-05-28 |
2015-12-11 |
Takeda Pharmaceutical |
Compuesto peptidico
|
CN104371019B
(zh)
|
2013-08-13 |
2019-09-10 |
鸿运华宁(杭州)生物医药有限公司 |
一种能与glp-1r特异性结合的抗体及其与glp-1的融合蛋白质
|
US10266577B2
(en)
|
2013-08-15 |
2019-04-23 |
Novo Nordisk A/S |
GLP-1 derivatives, and uses thereof
|
CA2933367A1
(en)
*
|
2013-12-13 |
2015-06-18 |
Restorsea, Llc |
Exfoliative hair retention-promoting formulation
|
KR101825048B1
(ko)
|
2014-12-31 |
2018-02-05 |
주식회사 제넥신 |
GLP 및 면역글로불린 하이브리드 Fc 융합 폴리펩타이드 및 이의 용도
|
DK3257524T3
(da)
|
2015-02-11 |
2020-11-23 |
Gmax Biopharm Llc |
Stabiliseret opløsningspræparat af farmaceutisk glp-1r-antistoffusionsprotein
|
CA3024962A1
(en)
|
2016-05-24 |
2017-11-30 |
Takeda Pharmaceutical Company Limited |
Peptide compound
|
ES2812698T3
(es)
|
2017-09-29 |
2021-03-18 |
Probiodrug Ag |
Inhibidores de glutaminil ciclasa
|
MX2020007598A
(es)
|
2018-02-02 |
2020-09-03 |
Novo Nordisk As |
Composiciones solidas que comprenden un agonista del peptido similar al glucagon tipo 1 (glp-1), una sal del acido n-(8-(2-hidroxibenzoil)amino)caprilico y un lubricante.
|
CN110305211A
(zh)
|
2018-03-20 |
2019-10-08 |
鸿运华宁(杭州)生物医药有限公司 |
Gipr抗体及其与glp-1的融合蛋白质,以及其药物组合物和应用
|
CN112521501A
(zh)
|
2019-09-18 |
2021-03-19 |
鸿运华宁(杭州)生物医药有限公司 |
Gipr抗体及其与glp-1的融合蛋白质,以及其药物组合物和应用
|
CN113597434B
(zh)
|
2019-12-31 |
2022-07-01 |
北京质肽生物医药科技有限公司 |
Glp-1和gdf15的融合蛋白以及其缀合物
|
JP2023545684A
(ja)
|
2020-09-30 |
2023-10-31 |
ベイジン キューエル バイオファーマシューティカル カンパニー,リミテッド |
ポリペプチドコンジュゲートおよび使用の方法
|